Sort by
Refine Your Search
-
Listed
-
Category
-
Country
-
Employer
- SciLifeLab
- University of Bergen
- Karolinska Institutet
- University of Groningen
- Centre for Genomic Regulation
- Fraunhofer-Gesellschaft
- Technical University of Denmark
- University of Utah
- ; University of Sussex
- ; University of Warwick
- AI|ffinity s.r.o. and University of Chemistry and Technology (UCT), Prague.
- American Institutes for Research
- Chalmers University of Technology
- Friedrich Schiller University Jena •
- Inria
- Inria Nancy - Grand Est
- International Centre for Translational Eye Research / Institute of Physical Chemistry, Polish Academy of Sciences
- KU Leuven (Coordinator)
- Monash University
- Rijksinstituut voor Volksgezondheid en Milieu (RIVM)
- Slovak University of Agriculture in Nitra
- Stockholm University
- University College Cork
- University of Adelaide
- University of Basel
- University of Montpellier
- University of South Carolina
- Uppsala University
- 18 more »
- « less
-
Field
-
. The project will be focused on addressing several challenges in structure-based drug design using artificial intelligence. Recently developed techniques for the prediction of the three-dimensional
-
the drug discovery process. The project will be focused on addressing several challenges in structure-based drug design using artificial intelligence. Recently developed techniques for the prediction
-
to establish a blueprint on how to design drug-like, potent, selective, and functional RNA ligands based on the 3D structure of the target and to advance our understanding of what drives potency and selectivity
-
. The main goal of this project is therefore to establish a blueprint on how to design drug-like, potent, selective, and functional RNA ligands based on the 3D structure of the target and to advance our
-
design drug-like, potent, selective, and functional RNA ligands based on the 3D structure of the target and to advance our understanding of what drives potency and selectivity of RNA ligands
-
very challenging. Therefore, high-throughput screening of drug-like molecules needs to also consider their synthetic viability. The aim of this project is to develop a deep learning and generative design
-
therapeutic applications in the treatment of various diseases and is promising evidence for the invention of new therapies. For example, 1,1-dimethylbiguanidine is an active component of the drug used in DM
-
perspectives. Frontiers in Molecular Biosciences , 8:697586, 2021. [4] D. J. Craik, et al. The future of peptide-based drugs. Chemical biology & drug design , 81(1):136-147, 2013. [5] D. Sch utz, et al . Peptide
-
study plan. For a doctoral degree, the equivalent of four years of full-time doctoral education is required. One Ph.D. position is available in cancer precision medicine using advanced machine learning
-
to Antaros Medical At Antaros Medical, we combine ground-breaking imaging with profound experience in drug development and deep knowledge of disease mechanisms. We are specialized in cardiorenal & metabolic